Skip to main content
Mohammed Asmal, MD, Infectious Disease, New York, NY

MohammedAsmalMD

Infectious Disease New York, NY

Venture Partner, OrbiMed Advisers

Dr. Asmal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Asmal's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School
    Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2006 - 2008
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2005 - 2019

Publications & Presentations

PubMed

Abstracts/Posters

  • The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
    Mohammed Asmal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar Hgb-204 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients
    HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 PatientsAugust 26th, 2020
  • Bluebird Bio Announces Topics for Gene Therapy Day, October Investor Presentation
    Bluebird Bio Announces Topics for Gene Therapy Day, October Investor PresentationOctober 6th, 2016